Evidence map›Paper›PMID 38315873›Full record

ArticleBlood advances2024

Impaired T cells and "memory-like" NK-cell reconstitution is linked to late-onset HCMV reactivation after letermovir cessation.

Chris David Lauruschkat, Ihsan Muchsin, Alice Felicitas Rein, Florian Erhard, Denise Grathwohl, Lars Dölken, Carolin Köchel, Anne Nehmer, Christine Susanne Falk, Götz Ulrich Grigoleit and 3 more

Abstract read
In one paragraph

Article in Blood advances, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors.

Chris David LauruschkatDepartment of Internal Medicine II, University Hospital of Wuerzburg, Würzburg, Germany.ORCID 0009-0005-3780-7320
Ihsan MuchsinInstitute for Virology and Immunobiology, Julius-Maximilians-University Wuerzburg, Würzburg, Germany.ORCID 0000-0002-0447-7864
Alice Felicitas ReinDepartment of Internal Medicine II, University Hospital of Wuerzburg, Würzburg, Germany.ORCID 0009-0007-7235-0105
Florian ErhardInstitute for Virology and Immunobiology, Julius-Maximilians-University Wuerzburg, Würzburg, Germany.ORCID 0000-0002-3574-6983
Denise GrathwohlDepartment of Internal Medicine II, University Hospital of Wuerzburg, Würzburg, Germany.
Lars DölkenInstitute for Virology and Immunobiology, Julius-Maximilians-University Wuerzburg, Würzburg, Germany.ORCID 0000-0002-4651-3544
Carolin KöchelDepartment of Internal Medicine II, University Hospital of Wuerzburg, Würzburg, Germany.
Anne NehmerDepartment of Internal Medicine II, University Hospital of Wuerzburg, Würzburg, Germany.
Christine Susanne FalkInstitute of Transplant Immunology, Medizinische Hochschule Hanover, Hanover, Germany.ORCID 0000-0003-1376-7318
Götz Ulrich GrigoleitDepartment of Internal Medicine II, University Hospital of Wuerzburg, Würzburg, Germany.ORCID 0000-0003-0847-8124
Hermann EinseleDepartment of Internal Medicine II, University Hospital of Wuerzburg, Würzburg, Germany.ORCID 0000-0002-7680-0819
Sebastian WursterDepartment of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, TX.ORCID 0000-0002-7784-7256
Sabrina KrausDepartment of Internal Medicine II, University Hospital of Wuerzburg, Würzburg, Germany.ORCID 0000-0001-8954-4220

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

abstractAllogeneic hematopoietic stem cell transplantation (alloSCT) is the only cure for many hematologic malignancies. However, alloSCT recipients are susceptible to opportunistic pathogens, such as human cytomegalovirus (HCMV). Letermovir prophylaxis has revolutionized HCMV management, but the challenge of late HCMV reactivations has emerged. Immunological surrogates of clinically significant HCMV infection (csCMVi) after discontinuation of letermovir remain to be defined. Therefore, we studied natural killer (NK)-cell reconstitution along with the global and HCMV pp65-specific T-cell repertoire of 24 alloSCT recipients at 7 time points before (day +90) and after (days +120-270) cessation of letermovir prophylaxis. Patients who experienced csCMVi had lower counts of IFN-γ+ HCMV-specific CD4+ and CD8+ T cells than HCMV controllers. Furthermore, patients with csCMVi displayed late impairment of NK-cell reconstitution, especially suppression of "memory-like" CD159c+CD56dim NK-cell counts that preceded csCMVi events in most patients. Moreover, several surrogates of immune reconstitution were associated with the severity of HCMV manifestation, with patients suffering from HCMV end-organ disease and/or refractory HCMV infection harboring least HCMV-specific T cells and "memory-like" NK cells. Altogether, our findings establish an association of delayed or insufficient proliferation of both HCMV-specific T cells and "memory-like" NK cells with csCMVi and the severity of HCMV manifestations after discontinuation of letermovir prophylaxis.

Indexed as

AcetatesCytomegalovirusCytomegalovirus InfectionsHematopoietic Stem Cell TransplantationKiller Cells, NaturalQuinazolinesAdultAgedAntiviral AgentsFemaleHumansImmunologic MemoryMaleMiddle AgedT-LymphocytesVirus ActivationAcetatesAntiviral AgentsletermovirQuinazolines

Identifiers

PMID38315873
PMCPMC11302378

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.